Angelica Welch

Novel combinations may be on the rise for the treatment of mantle cell lymphoma.

In an interview with CURE at the Interdisciplinary Prostate Cancer Congress, Celesita Higano, M.D., discussed the early use of chemotherapy, the potential for PARP inhibitors and the evolving role of radium-223 in prostate cancer.

PARP inhibitors like Rubraca and Lynparza continue to shape the treatment landscape of ovarian cancer.

Mohammad Jahanzeb, M.D., discusses the SystHERs study, which is looking closely at current treatment methods for HER2- positive metastatic breast cancer (MBC).

A recent study investigated racial and ethnic disparities in guideline-based care for cervical cancer.

In an interview with CURE, lead study author Scott Tagawa, M.D., discussed the latest findings with sacituzumab govitecan in patients with metastatic urothelial cancer.

As the treatment landscape of head and neck cancer has changed significantly over the past year, immunotherapy has emerged as a key player in patient care.

Immunotherapy has drastically shaped the treatment of lung cancer. Vassiliki A. Papadimitrakopoulou, M.D., looks forward to what's next.

Charles Drake, M.D., Ph.D.. is optimistic about immunotherapy as it continues to move toward the frontline setting in GU cancers.

Intensity-modulated radiation therapy (IMRT) proved to lower the incidence of gastrointestinal toxicities in patients with gynecologic malignancies, according to the results from a recent study.

The number of positive lymph nodes can help guide treatment for locally advanced head and neck cancer, according to a recent study.

David McDermott, M.D. discusses new advances made to treat kidney cancer.

CURE spoke with Eric Smith, M.D., Ph.D. about immunotherapy and other advances being made in multiple myeloma.

Padeliporfin vascular-targeted photodynamic therapy may be a promising option for men with low-risk prostate cancer, according to the results of a recent study.

CURE spoke with Michael J. Overman, M.D. about the promise of anti-PD-1 therapy for patients with MSI-H colorectal cancer.

A study being conducted at the MD Anderson Cancer Center is looking at whether certain patients with breast cancer can forgo surgery.

Jenny C. Chang, M.D., discusses the future of breast cancer care, and what role molecular testing will play.

CURE spoke with Neeraj Agarwal, M.D., about the underreporting and underemphasizing of toxicities with PD-1 inhibitors in renal cell carcinoma.

Vaccines are currently being tested in their potential to improve immunotherapy responses for patients with renal cell carcinoma.